Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Merus N.V. (NASDAQ:MRUS) are Biotechnology companies, competing one another. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 60 0.00 34.37M -0.46 0.00
Merus N.V. 16 0.00 12.82M -1.29 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of CRISPR Therapeutics AG and Merus N.V.

Profitability

Table 2 provides the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 57,235,636.97% -2.6% -2%
Merus N.V. 80,985,470.63% -33.2% -13.2%

Liquidity

The current Quick Ratio of CRISPR Therapeutics AG is 8.3 while its Current Ratio is 8.3. Meanwhile, Merus N.V. has a Current Ratio of 5.6 while its Quick Ratio is 5.6. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Merus N.V.

Analyst Recommendations

Recommendations and Ratings for CRISPR Therapeutics AG and Merus N.V. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 3 3.00
Merus N.V. 0 0 1 3.00

CRISPR Therapeutics AG’s upside potential currently stands at 8.55% and an $72 consensus price target. Merus N.V. on the other hand boasts of a $20 consensus price target and a 17.03% potential upside. Based on the data delivered earlier, Merus N.V. is looking more favorable than CRISPR Therapeutics AG, analysts view.

Institutional and Insider Ownership

Institutional investors held 46.8% of CRISPR Therapeutics AG shares and 49.2% of Merus N.V. shares. Insiders held 0.4% of CRISPR Therapeutics AG shares. Competitively, Merus N.V. has 30.47% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 1% 49.37% 59.3% 63.07% 101.48% 153.31%
Merus N.V. -1.33% 4.1% -1.45% 24.6% 41.88% 16.14%

For the past year CRISPR Therapeutics AG was more bullish than Merus N.V.

Summary

CRISPR Therapeutics AG beats Merus N.V. on 7 of the 10 factors.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link